Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 2/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24630336 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL14367909 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL5579743 | 0.77 | DPP4 (0.39) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL6618896 | 0.76 | — | — | |
| SCHEMBL4044697 | 0.76 | — | — | |
| SCHEMBL2920884 | 0.76 | — | — | |
| SCHEMBL13857686 | 0.75 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL16706476 | 0.75 | TASP1 (0.42) | SMN1; SMN2 | |
| SCHEMBL15159359 | 0.72 | KDM4E (0.43) | ALDH1A1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL13645737 | 0.71 | BIRC2 (0.42) | ALDH1A1KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539298-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371359-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, P4HA1 | ALDH1A1 1662/4885KDM4E 1802/4885MAPT 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.